Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group.

N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

2.

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group.

Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8.

PMID:
26450639
3.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

4.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.

N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

5.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

6.

Unusual recurrent rectal carcinoma: a cancer field theory viewpoint.

Vyslouzil K, Brychtova S, Zboril P, Skalicky P, Vomackova K, Bezdekova M, Brychta T.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Sep;158(3):433-7. doi: 10.5507/bp.2012.091. Epub 2012 Nov 2.

7.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group.

Diabetes Care. 2012 Jun;35(6):1232-8. doi: 10.2337/dc11-1926. Epub 2012 Apr 9.

8.

Analysis of Snail-1, E-cadherin and claudin-1 expression in colorectal adenomas and carcinomas.

Bezdekova M, Brychtova S, Sedlakova E, Langova K, Brychta T, Belej K.

Int J Mol Sci. 2012;13(2):1632-43. doi: 10.3390/ijms13021632. Epub 2012 Feb 2.

9.

[Fibroblasts--known or unknown cells].

Brychtová S, Bezdeková M, Brychta T.

Cesk Patol. 2010 Apr;46(2):29-32. Review. Czech.

PMID:
21280279
10.

Mass ascites in Mulibrey nanism.

Husova L, Husa P, Brychta T.

J Pediatr Endocrinol Metab. 2010 Sep;23(9):863-5. No abstract available.

PMID:
21175083
11.

[Persisting symptoms, diastolic dysfunction and decreased coronary flow reserve after succesful correction of aortic recoarctation].

Sebo M, Zatocil T, Necasová A, Brychta T, Cerný J, Kala P, Spinar J.

Vnitr Lek. 2010 Mar;56(3):247-50. Slovak.

PMID:
20394212
12.

Comparison of lipid lowering effect of sibutramine in patients treated or not treated with statins--3 month follow-up.

Svacina S, Owen K, Hendl J, Matoulek M, Brychta T.

Prague Med Rep. 2007;108(4):333-8.

PMID:
18780645
13.

The role of vascular endothelial growth factors and their receptors in malignant melanomas.

Brychtova S, Bezdekova M, Brychta T, Tichy M.

Neoplasma. 2008;55(4):273-9.

PMID:
18505336
14.

Immunohistochemical assessment of E-cadherin and beta-catenin in trichofolliculomas and trichoepitheliomas.

Bezdekova M, Brychtova S, Sedlakova E, Steigerova J, Hlobilkova A, Bienova M, Kucerova R, Brychta T, Krejci V, Kolar Z.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Dec;151(2):251-5.

15.

Nestin expression in cutaneous melanomas and melanocytic nevi.

Brychtova S, Fiuraskova M, Hlobilková A, Brychta T, Hirnak J.

J Cutan Pathol. 2007 May;34(5):370-5.

PMID:
17448190
16.

[Residual echocardiographic findings and NT-proBNP in asymptomatic adult patients after radical correction of Fallot's tetralogy].

Zatocil T, Manousek J, Brychta T, Necasová A, Spinar J.

Vnitr Lek. 2007 Feb;53(2):116-22. Czech.

PMID:
17419171
17.

The metabolic syndrome: relationship between insulin sensitivity and the role of peroxisome proliferator-activated receptors (PPARs) in saccharide and lipid metabolism.

Yahia RB, Lichnovská R, Brychta T.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005 Dec;149(2):237-41. Review.

18.

[The role of intermedial filament nestin in malignant melanoma progression].

Brychtová S, Fiurásková M, Brychta T, Hirnák J.

Cesk Patol. 2005 Oct;41(4):143-5. Czech.

PMID:
16382989
19.

[ST-segment resolution as a simple tool for the assessment of successful primary coronary intervention at a microvascular level].

Poloczek M, Kala P, Neugebauer P, Brychta T, Bocek O, Jerábek P, Parenica J, Vytiska M, Semrád B.

Vnitr Lek. 2004 Oct;50(10):740-5. Czech.

PMID:
15633928
20.

Proto-oncogene c-myc in uterine cervix carcinogenesis.

Brychtová S, Brychta T, Sedláková E, Kolár Z.

Neoplasma. 2004;51(2):84-9.

PMID:
15190416

Supplemental Content

Loading ...
Support Center